Upstream Bio to present additional Phase 2 VIBRANT trial analyses on March 1
Upstream Bio will present additional efficacy endpoint analyses from its Phase 2 VIBRANT trial of verekitug in chronic rhinosinusitis with nasal polyps during a late-breaking poster session at the AAAAI meeting on March 1, 2026. These new analyses adjust efficacy data for concomitant rescue therapy use in the trial cohort.
1. Presentation Announcement
Upstream Bio will showcase new data from its Phase 2 VIBRANT trial of verekitug during a late-breaking poster session at the AAAAI Annual Meeting on Sunday, March 1, 2026, from 9:45 to 10:45 a.m. EST at the Philadelphia Convention Center, Hall E (Poster L60).
2. VIBRANT Trial Additional Analyses
The presentation will feature efficacy and safety analyses of verekitug in chronic rhinosinusitis with nasal polyps, specifically assessing outcomes after adjusting for use of rescue therapies, providing deeper insight into the drug’s performance in the trial population.
3. Verekitug Profile and Clinical Pipeline
Verekitug is a fully human IgG1 monoclonal antibody targeting the TSLP receptor to inhibit upstream inflammatory signaling. It has advanced into three global Phase 2 trials—VIBRANT in CRSwNP, VALIANT in severe asthma (both completed), and the ongoing VENTURE study in COPD—plus a long-term VALOUR extension.